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Twelve-Month Efficacy and Safety of 0.5 mg
or 2.0 mg Ranibizumab in Patients with
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Zhengrong Li, PhD,6 Roman G. Rubio, MD,6 Phillip Lai, MD,6 for the HARBOR Study Group*
Objective: To evaluate the 12-month efficacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg
administered monthly and on an as-needed (PRN) basis in treatment-naïve patients with subfoveal neovascular
age-related macular degeneration (wet AMD).
Design: A 24-month, phase III, randomized, multicenter, double-masked, dose-response study.
Participants: Patients aged 50 years with subfoveal wet AMD.
Methods: Patients (n  1098) were randomized to receive ranibizumab 0.5 mg or 2.0 mg intravitreal
injections administered monthly or on a PRN basis after 3 monthly loading doses.
Main Outcome Measures: The primary efficacy end point was the mean change from baseline in best-
corrected visual acuity (BCVA) at month 12. Key secondary end points included the mean number of ranibizumab
injections, the mean change from baseline in central foveal thickness (CFT) over time, and the proportion of
patients who gained 15 letters of BCVA. Unless otherwise specified, end point analyses were performed using
the last-observation-carried-forward method to impute missing data.
Results: At month 12, the mean change from baseline in BCVA for the 4 groups was 10.1 letters (0.5 mg
monthly),8.2 letters (0.5 mg PRN),9.2 letters (2.0 mg monthly), and8.6 letters (2.0 mg PRN). The proportion
of patients who gained 15 letters from baseline at month 12 in the 4 groups was 34.5%, 30.2%, 36.1%, and
33.0%, respectively. The mean change from baseline in CFT at month 12 in the 4 groups was 172.0 m,
161.2 m, 163.3 m, and 172.4 m, respectively. The mean number of injections was 7.7 and 6.9 for the
0.5-mg PRN and 2.0-mg PRN groups, respectively. Ocular and systemic safety profiles were consistent with
previous ranibizumab trials in AMD and comparable between groups.
Conclusions: At month 12, the ranibizumab 2.0 mg monthly group did not meet the prespecified superiority
comparison and the ranibizumab 0.5 mg and 2.0 mg PRN groups did not meet the prespecified noninferiority (NI)
comparison. However, all treatment groups demonstrated clinically meaningful visual improvement (8.2 to
10.1 letters) and improved anatomic outcomes, with the PRN groups requiring approximately 4 fewer injections
(6.9–7.7) than the monthly groups (11.2–11.3). No new safety events were observed despite a 4-fold dose
escalation in the study. The pHase III, double-masked, multicenter, randomized, Active treatment-controlled
study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab administered monthly or on an as-needed
Basis (PRN) in patients with subfoveal neOvasculaR age-related macular degeneration (HARBOR) study con-
firmed that ranibizumab 0.5 mg dosed monthly provides optimum results in patients with wet AMD.
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
Ophthalmology 2013;120:1046–1056
© 2013 by the American Academy of Ophthalmology. Open access under CC BY-NC-ND license.*Group members listed online in Appendix 1 (available at http://aaojournal.org).
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iAge-related macular degeneration (AMD) is the leading cause
of blindness among individuals aged 50 years or older in the
United States and many other parts of the world.1,2 Choroidal
neovascularization (CNV), the hallmark of neovascular or wet
AMD, is responsible for the majority of cases of severe vision
loss due to AMD.3 The development of CNV lesions is pro-
moted by increased expression of vascular endothelial growth
factor A (VEGF-A), with highly vascularized lesions express-
ing the highest levels.4 Although the pathogenesis of neovas-
T
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Published by Elsevier Inc. Open access under CC BY-NC-ND license.ular AMD is not fully understood, inhibition of VEGF-A has
een shown to block intraocular neovascularization in vivo.5
ationale for Higher Doses of Ranibizumab
n Wet Age-Related Macular Degenerationhe pivotal phase III clinical studies, Anti-VEGF Antibody
or the Treatment of Predominantly Classic Choroidal
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Busbee et al  HARBOR Study 1-year ResultsNeovascularization in Age-Related Macular Degenera-
tion (ANCHOR)6,7 and Minimally Classic/Occult Trial
of the Anti-VEGF Antibody Ranibizumab in the Treat-
ment of Neovascular Age-Related Macular Degeneration
(MARINA),8 established that intravitreal administration of
ranibizumab 0.3 mg and 0.5 mg (Lucentis; Genentech, Inc,
South San Francisco, CA) significantly improves visual
acuity (VA) in wet AMD. These 2 studies led to the US
Food and Drug Administration (FDA) approval of monthly
intravitreal ranibizumab 0.5 mg for the treatment of neo-
vascular AMD in 2006. In these pivotal trials, most of the
functional and anatomic outcomes favored the 0.5 mg dose
of ranibizumab compared with the 0.3 mg dose. For exam-
ple, in the ANCHOR6,7 study at month 12, the mean VA
improvement with ranibizumab 0.5 mg was 11.3 Early
Treatment Diabetic Retinopathy Study (ETDRS) letters (at
a distance of 2 meters) versus 8.5 letters with the 0.3 mg
dose. Furthermore, 40.3% and 35.7% of patients receiving
ranibizumab 0.5 mg or 0.3 mg gained15 ETDRS letters at
month 12, respectively. Likewise, in the MARINA8 study at
month 12, 33.8% of patients treated with 0.5 mg had a
15-letter gain in best-corrected visual acuity (BCVA)
compared with 24.8% treated with 0.3 mg. Patients in the
MARINA study had a mean BCVA improvement at month
12 of 7.2 letters when treated with ranibizumab 0.5 mg and
6.5 letters when treated with ranibizumab 0.3 mg. The data
from ANCHOR and MARINA suggested that treatment
with higher doses of ranibizumab may lead to a further
increase in efficacy.
Before the FDA approval of ranibizumab 0.5 mg for pa-
tients with wet AMD, an open-label, uncontrolled, randomized
clinical study demonstrated that doses of ranibizumab up to 2.0
mg were safe and well tolerated in this patient population.9
More recently, the investigator-sponsored double dose (DoDo)
trial demonstrated trends toward higher efficacy with less fre-
quent injections using ranibizumab 1.0 mg compared with 0.5
mg for naïve, wet AMD (Busbee B, Wu C, McCain M.
Predictive factors for repeat dosing in wet AMD: results
from the DoDo trial. Presented at: the American Society
of Retina Specialists 29th Annual Meeting, August 20 –
24, 2011, Boston, MA). Further study of higher dosing
revealed favorable initial results when patients previ-
ously treated with ranibizumab 0.5 mg were switched to
2.0 mg in the investigator-sponsored Super-dose Anti-
VEgF (SAVE) trial.10 These small trials suggested the
potential of enhanced efficacy with higher dosing of
ranibizumab.
Rationale for As-Needed Dosing in Wet
Age-Related Macular Degeneration
On the basis of results from several phase III/IIIb studies, in
which VA outcomes were markedly better in patients re-
ceiving ranibizumab on a monthly basis (ANCHOR6,7 and
MARINA8) than in patients receiving 3 monthly loading
doses, followed by prescheduled quarterly injections thereafter
(Phase IIIb, Multicenter, Randomized, Double-Masked, Sham
Injection-Controlled Study of the Efficacy and Safety of
Ranibizumab in Subjects with Subfoveal Choroidal Neovas- yularization with or without Classic CNV Secondary to Age-
elated Macular Degeneration study [PIER]),11,12 the
anibizumab US prescribing information recommended
onthly injections for optimal VA outcomes. However,
ecause monthly injections represent a burden on patients
nd their caregivers, most retina specialists use individual-
zed dosing regimens based predominantly on optical co-
erence tomography (OCT) to treat patients with wet AMD
Jumper MJ, Mittra RA. American Society of Retina Spe-
ialists PAT Survey, 2011).
Quantitative and qualitative examination findings on
CT have become an integral part of the decision-making
ormula for treating patients on an individualized basis as
pposed to monthly dosing for all patients.
Before the recent Comparison of Age-related macular
egeneration Treatments Trials (CATT)13,14 and alternative
reatments to Inhibit VEGF in Age-related choroidal Neo-
ascularization (IVAN)15 multicenter studies, an OCT-
uided treatment approach had been evaluated only in the
0-patient, phase II, open-label, nonrandomized prospective
CT imaging of patients with neovascular AMD treated
ith intraocular Ranibizumab (PrONTO)16,17 trial. In this
rial, patients received 3 monthly doses of ranibizumab 0.5
g, followed by monthly evaluation and pro re nata (PRN)
reatment guided by specific VA and imaging criteria for 24
onths. The visual results from this small cohort were
avorable and similar to the results from the ANCHOR and
ARINA trials with fewer injections over the study period.
he PrONTO study, along with the adoption of alternative
osing regimens by many retina specialists, supported the
valuation of PRN dosing in wet AMD.
Presented within are the 12-month results of the pHase
II, double-masked, multicenter, randomized, Active treat-
ent-controlled study of the efficacy and safety of 0.5 mg
nd 2.0 mg Ranibizumab administered monthly or on an
s-needed Basis (PRN) in patients with subfoveal neOvasculaR
ge-related macular degeneration (HARBOR) trial, which was
onducted to evaluate the potential beneficial effects of both
higher dose and PRN dosing of ranibizumab in patients
ith wet AMD.
atients and Methods
tudy Design
ARBOR is a 24-month, phase III, randomized, multicenter,
ouble-masked, active treatment-controlled study (ClinicalTrials.
ov identifier: NCT00891735) with 100 investigator sites and
098 randomized patients. The study was conducted in accordance
ith Good Clinical Practice (International Conference on Harmo-
ization of Technical Requirements for Registration of Pharma-
euticals for Human Use [ICH] E6), applicable FDA regulations,
nd the Health Insurance Portability and Accountability Act. The
tudy protocol was approved by respective institutional review
oards before the start of the study, and all participants provided
ritten informed consent.
creening and Eligibility
atients were eligible for the HARBOR trial if they were aged 50
ears or older and fulfilled the following inclusion criteria for the
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Ophthalmology Volume 120, Number 5, May 2013study eye: (1) BCVA of 20/40 to 20/320 (Snellen equivalent),
using ETDRS charts (at a distance of 4 meters); (2) active subfo-
veal lesions with classic CNV, some classic CNV component, or
purely occult CNV; (3) total area of lesion 12 disc areas (DA) or
30.48 mm2; and (4) total CNV area constitutes 50% of total
lesion area based on fluorescein angiography (FA). For the inclu-
sion of purely occult or occult with some classic CNV, activity of
the lesion had to be demonstrated by one of several criteria. This
included a 10% increase in CNV lesion size on interval visits, a
documented visual loss of 1 line of Snellen vision, or the
presence of hemorrhage at presentation. Key exclusion criteria (for
the study eye) were a history of vitrectomy surgery; prior treatment
with photodynamic therapy with verteporfin, external beam radi-
ation therapy, or transpupillary thermotherapy; previous intravit-
real drug delivery; previous subfoveal laser photocoagulation;
uncontrolled blood pressure; atrial fibrillation not managed by the
patient’s primary care physician or cardiologist within 3 months of
the screening visit; or a history of stroke within 3 months of the
screening visit.
Safety Run-in Assessment for the Ranibizumab
2.0 mg Dose
A 10-patient safety run-in assessment to determine the safety and
tolerability of a single 2.0 mg dose of intravitreal ranibizumab was
conducted before the 4-arm, randomized phase of the HARBOR
trial. Each patient received a single injection at day 0 and had
safety assessment visits scheduled on days 3, 7, 14, 28, 60, and 90.
The HARBOR Data Monitoring Committee evaluated the first
month of safety data for this group; they recommended no change
to the study protocol, and enrollment in the randomized phase of
the HARBOR trial commenced.
An additional safety assessment was performed after the first
40 evaluable patients in the 4-arm, randomized phase of the study
(20 patients receiving ranibizumab 0.5 mg monthly or PRN and 20
patients receiving ranibizumab 2.0 mg monthly or PRN) received
at least 2 study treatments. No dose-limiting criteria were observed
for this group, and Data Monitoring Committee review of these
safety data resulted in a recommendation to continue with the
randomized phase of the HARBOR trial.
Randomization
After written informed consent was obtained, and the central
reading center confirmed that patients met all eligibility require-
ments, each patient received a computer-generated subject number
on day 0, which randomly assigned patients in a 1:1:1:1 ratio to 1
of 4 ranibizumab treatment groups: 0.5 mg monthly, 0.5 mg PRN,
2.0 mg monthly, and 2.0 mg PRN. The 0.5 mg and 2.0 mg doses
were both injected in a volume of 0.05 ml. Randomization was
stratified by VA at day 0 (54 letters [approximate Snellen equiv-
alent 20/80] vs. 55 letters [approximate Snellen equivalent
20/80]), CNV classification at baseline (predominantly classic,
minimally classic, or purely occult), and study center. One eye was
chosen as the study eye for each patient. All study site personnel,
the designated physician(s), central reading center personnel, pa-
tients, and the sponsor and its agents were masked to treatment
drug dose assignment (0.5 mg vs. 2.0 mg). Treatment frequency
(ie, monthly vs. PRN dosing) was not masked to patient and site
personnel.
Only the randomization provider and an external and indepen-
dent statistical coordinating center responsible for performing in-
terim analyses for the Data Monitoring Committee review, not
otherwise involved in the study, had access to the unmasking code.
In addition, an independent review of fundus photographs, FAs,
and OCT images was performed at the central reading center to p
1048rovide an objective, masked assessment of these evaluations. The
entral reading center review team consisted of graders and oph-
halmologists experienced in clinical trials.
tudy Assessment and Treatment Schedule
he 4-arm, randomized phase of the study consisted of a screening
eriod of up to 28 days and a 24-month treatment period. The
rimary efficacy end point was evaluated at month 12 (treatment
eriod from day 0 [first intravitreal injection of ranibizumab] to
onth 11). Safety and ocular parameters were assessed on day 7;
ubsequently, all patients had scheduled monthly visits for evalu-
tion of safety and efficacy. Patients in the monthly dosing groups
ad a safety evaluation before receiving the next monthly ranibi-
umab injection. Patients in the PRN groups also had monthly
afety evaluations, but received ranibizumab monthly for the first
doses only. At the month 3 visit and thereafter, patients in the
RN groups received ranibizumab only if the investigating oph-
halmologist determined that retreatment criteria were met (a 5-
etter decrease in BCVA from the previous visit OR any evidence
f disease activity on spectral-domain [SD OCT]; Table 1, avail-
ble at http://aaojournal.org). At each monthly visit, all patients
eceived an assessment for BCVA using the ETDRS protocol; a
omplete eye examination and vital signs; a review of concom-
tant medications; adverse events (AEs), and SD-OCT using
irrus HD-OCT III (Carl Zeiss Meditec, Inc., Dublin, CA).
luorescein angiography and fundus photography were per-
ormed at screening and at months 3, 6, and 12.
utcome Measures
he primary end point was the mean change from baseline in
CVA at month 12. Key secondary end points included the mean
umber of ranibizumab injections up to, but not including, month
2; the mean change from baseline in central foveal thickness
CFT) based on SD-OCT over time to month 12; the proportion of
atients who gained 15 letters from baseline in BCVA at month
2; and the proportion of patients with a Snellen equivalent of
20/40.
An exploratory VA end point evaluated was the proportion of
atients with a Snellen equivalent of 20/200, and additional VA
nd points included the proportion of patients who lost15 letters
rom baseline in BCVA at month 12.
Safety assessments included ocular and systemic safety events
hrough month 12. Assessments of targeted events included study
ye serious adverse events (SAEs), Antiplatelet Trialists’ Collab-
ration (APTC) arterial thromboembolic events (ATEs), and SAEs
otentially related to systemic VEGF-A inhibition.
tatistical Analysis
fficacy Analyses. Unless otherwise specified, the intent-to-treat
rinciple was used for efficacy analyses, with missing data im-
uted using the last-observation-carried-forward method. Efficacy
nalyses were stratified by baseline BCVA score (54 letters,55
etters) and baseline CNV classification (predominantly classic,
inimally classic, purely occult). Patients were analyzed accord-
ng to the treatment assignment at randomization. For efficacy end
oints using continuous variables (except for the mean number of
anibizumab injections), mean change from baseline at 12 months
as compared between each treatment group and the standard
reatment group (0.5 mg monthly) using the t test from a stratified
nalysis of variance or a stratified analysis of covariance model.
or efficacy end points using binary variables, the proportion of
atients meeting the end point was compared between each treat-
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Busbee et al  HARBOR Study 1-year Resultsment group and the standard treatment group using the Cochran–
Mantel–Haenszel chi-square test. The mean number of injections
during the first 12-month treatment period was compared between
each treatment group and the standard treatment group using a
stratified Wilcoxon test, and only patients who received at least 1
ranibizumab injection in the study eye were included in this
analysis. Three primary end point comparisons were performed
between the standard treatment group and each of the remaining 3
groups. Noninferiority (NI) tests with a prespecified NI margin of
4 letters comparing the 0.5 mg PRN with the 0.5 mg monthly
group and the 2.0 mg PRN with the 0.5 mg monthly group were
performed. A superiority test assessed the differences between the
2.0 mg monthly and 0.5 mg monthly groups. A Hochberg–Bonferroni
approach was used to control the overall significance level for
these 3 primary comparisons. The sample size of 1100 randomized
patients ensured 80% power in the intent-to-treat population anal-
ysis for these 3 primary comparisons.
Safety Analyses. Safety was assessed through collection and
summary of ocular and nonocular AEs, SAEs, ocular assessments,
deaths, laboratory results, vital signs, and antibodies to ranibi-
zumab. At each study visit, nondirective questioning was used to
elicit AE reports from patients. All AEs and SAEs, whether
volunteered by the patient, discovered by study site personnel
during questioning, or detected by examination, laboratory testing,
or other means, were recorded in the patient record and case report
forms. Safety analyses included all patients receiving 1 ranibi-
zumab injection. Patients were analyzed according to actual treat-
ment received.
Results
Patient Characteristics and Disposition
Between July 2009 and August 2010, recruitment of HARBOR
included 1098 patients in 100 study centers across the United
States and assigned to ranibizumab 0.5 mg monthly (n 276), 0.5
mg PRN (n  275), 2.0 mg monthly (n  274), or 2.0 mg PRN
(n  273). Overall, 1097 patients were eligible for the study; 1
patient was randomized before screen failure, and no baseline or
post-baseline data were reported for this patient; therefore, the
patient was excluded from analysis. In total, 94.5% of patients
remained in the study through month 12; 5.5% of patients discon-
Table 2. Pat
Status/Primary Reason for Discontinuation, n (%)
0.5 mg M
(n  2
Received study drug in study eye before month 12 274 (99
Discontinued study before month 12 (total) 17 (6.
AE 2 (0.
Death 8 (2.
Lost to follow-up 2 (0.
Physician’s decision to withdraw patient from study 1 (0.
Patient’s decision to withdraw 4 (1.
Discontinued treatment before month 12 (total) 21 (7.
AE 2 (0.
Death 8 (2.
Lost to follow-up 2 (0.
Physician’s decision to discontinue treatment 1 (0.
Patient’s decision to discontinue treatment 8 (2.AE  adverse event; PRN  pro re nata.inued the study; the most common reason for study discontinua-
ion was based on the patient’s decision to withdraw (Table 2).
iscontinuation rates were balanced among the 4 treatment
roups. All but 2 patients received the study drug in the study eye
before the first injection, 1 patient withdrew from the study and 1
atient was lost to follow-up).
The mean age of patients was 79 years; 59% were female, and
he majority was Caucasian. The mean baseline VA was between
3.5 and 54.5 letters (approximate Snellen equivalent of 20/80)
nd mean baseline CFT ranged from 333 to 348 m among the 4
ohorts (Table 3). Overall, approximately 46% of patients had
inimally classic CNV lesions, 16% had predominantly classic
esions, and 38% had purely occult CNV. The total area of CNV
esion size was 3.0 to 3.3 DA. All variables were well balanced
mong the 4 treatment groups.
fficacy Outcomes
isual Acuity End Points. The HARBOR study did not meet its
rimary end point, which comprised 3 comparisons: a superiority
omparison (2.0 mg monthly vs. 0.5 mg monthly) and 2 NI
omparisons (2.0 mg PRN and 0.5 mg PRN vs. 0.5 mg monthly;
ig 1). There was no evidence that the 2.0 mg monthly dosing
egimen was superior to the 0.5 mg monthly regimen (model-
djusted mean difference, 1.1 letters; 95.1% confidence interval
CI], 3.4 to 1.3; P  0.8145). The 0.5 mg PRN and 2.0 mg PRN
egimens failed to meet the 4-letter NI margin when compared
ith the 0.5 mg monthly regimen. The NI comparison between 0.5
g PRN and 0.5 mg monthly had a model-adjusted mean differ-
nce of 2.0 letters (97.5% CI, 4.5 to 0.6), and the NI compar-
son between 2.0 mg PRN and 0.5 mg monthly had a model-
djusted mean difference of 1.6 letters (98.4% CI, 4.4 to 1.1).
Although the primary end point was not met, all 4 treatment
roups demonstrated significant and clinically meaningful in-
reases in BCVA at month 12 compared with baseline. This
mprovement from baseline BCVA was observed starting at day 7,
ith further improvements over the course of the study that were
ustained through month 12. The mean gains in BCVA (ETDRS
etters) from baseline to 12 months were 10.1 (0.5 mg monthly),
.2 (0.5 mg PRN), 9.2 (2.0 mg monthly), and 8.6 (2.0 mg PRN).
he BCVA gains were achieved with an average of 11.3 (0.5 mg
onthly), 7.7 (0.5 mg PRN), 11.2 (2.0 mg monthly), and 6.9 (2.0
g PRN) injections over 12 months (Fig 2).
Disposition
Ranibizumab Treatment Groups
0.5 mg PRN
(n  275)
2.0 mg Monthly
(n  274)
2.0 mg PRN
(n  273)
275 (100.0) 274 (100.0) 272 (99.6)
12 (4.4) 16 (5.8) 15 (5.5)
2 (0.7) 0 0
4 (1.5) 5 (1.8) 5 (1.8)
2 (0.7) 2 (0.7) 2 (0.7)
0 0 0
4 (1.5) 9 (3.3) 8 (2.9)
16 (5.8) 18 (6.6) 18 (6.6)
1 (0.4) 0 1 (0.4)
4 (1.5) 5 (1.8) 4 (1.5)
2 (0.7) 3 (1.1) 3 (1.1)
0 1 (0.4) 0
9 (3.3) 9 (3.3) 10 (3.7)ient
onthly
75)
.6)
2)
7)
9)
7)
4)
5)
6)
7)
9)
7)
4)
9)1049
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Ophthalmology Volume 120, Number 5, May 2013Other key efficacy end points are summarized in Table 4. The
proportion of patients who gained 15 letters (3 lines) from
baseline in BCVA at month 12 was 34.5% (0.5 mg monthly),
30.2% (0.5 mg PRN), 36.1% (2.0 mg monthly), and 33.0% (2.0 mg
Table 3. Patient Demographics and B
0.5 mg Monthly
(n  275)
Age (yrs)
Mean (SD) 78.8 (8.4)
Range 53.0–97.0
Sex, n (%)
Male 113 (41.1)
Female 162 (58.9)
Race, n (%)
White 265 (96.4)
VA (No. of letters, 0–100)
Mean (SD)* 54.2 (13.3)
Range 3–78
54 letters, n (%) 126 (45.8)
55 letters, n (%) 149 (54.2)
CFT (m)
Mean (SD) 348.3 (146.3)
CNV lesion type, n (%)
Minimally classic 127 (46.2)
Predominantly classic 42 (15.3)
Purely occult 106 (38.5)
Total area of lesion (DA)
Mean (SD) 3.39 (2.17)
Range 0.13–11.74
Total area of CNV (DA)
Mean (SD) 3.27 (2.12)
Range 0.13–11.74
Total area of CNV leakage (DA)
Mean (SD) 3.48 (2.08)
Range 0.33–11.74
CFT  central foveal thickness; CNV  choroidal neo
standard deviation; VA  visual acuity.
*Approximate Snellen equivalent of 20/80.
0.5 mg PRN
2.0 mg PRN
2.0 mg monthly
NI margin of 4 letters
–4.5 –2.0 0.6 
–4.4 –1.6 1.1 
–3.4 –1.1 1.3 
–5.0 –4.0 –3.0 –2.0 –1.0 0.0 1.0 2.0 3.0 4.0 5.0
0.5 mg Monthly Better 0.5 mg Monthly Worse
Noninferiority Comparison
Superiority Comparison
 
Figure 1. Mean change from baseline in best-corrected visual acuity
(BCVA) at month 12 using Hochberg-adjusted confidence intervals (CIs)*
(adjusted difference in mean change in BCVA compared with 0.5 mg monthly†).
*Prespecified in HARBOR statistical analysis plan. †Adjusted for baseline BCVA
score (54 letters,55 letters) and choroidal neovascularization (CNV) clas-
sification; the last-observation-carried-forward (LOCF) method was used topimpute missing data. NI  noninferiority; PRN  pro re nata.
1050RN). The proportion of patients who had a Snellen equivalent of
20/40 at month 12 was 52.4% (0.5 mg monthly), 46.2% (0.5 mg
RN), 50.0% (2.0 mg monthly), and 43.6% (2.0 mg PRN). The
roportion of patients with a Snellen equivalent of 20/200 at
onth 12 was 7.3% (0.5 mg monthly), 8.4% (0.5 mg PRN), 11.3%
2.0 mg monthly), and 12.1% (2.0 mg PRN).
Another commonly reported VA end point, the proportion of
atients who lost 15 letters from baseline at month 12, was
xplored post hoc. At month 12, the proportion of patients who lost
15 letters from baseline at month 12 was 97.8% (0.5 mg
onthly), 94.5% (0.5 mg PRN), 93.4% (2.0 mg monthly), and
4.9% (2.0 mg PRN) (Table 4).
natomic End Points and Pro Re Nata Cohort
nalysis
ptical Coherence Tomography End Points. The mean change
rom baseline in CFT by SD-OCT over time up to month 12 is
epicted in Figure 3. All groups showed a rapid decrease in CFT
t day 7 that continued through month 3 and was sustained from
onth 3 to 12. At month 12, the mean reduction from baseline was
72.0 m (0.5 mg monthly), 161.2 m (0.5 mg PRN), 163.3 m
2.0 mg monthly), and 172.4 m (2.0 mg PRN).
Optical Coherence Tomography Analysis in the Pro Re Nata
roups. Further exploratory analyses of the criteria for retreat-
ent in the PRN groups revealed that between 51% and 62% of
e Ocular Characteristics (Study Eye)
Ranibizumab Treatment Groups
0.5 mg PRN
(n  275)
2.0 mg Monthly
(n  274)
2.0 mg PRN
(n  273)
78.5 (8.3) 79.3 (8.3) 78.3 (8.3)
53.0–97.0 50.0–96.0 54.0–98.0
112 (40.7) 104 (38.0) 117 (42.9)
163 (59.3) 170 (62.0) 156 (57.1)
268 (97.5) 268 (97.8) 261 (95.6)
54.5 (11.7) 53.5 (13.1) 53.5 (13.2)
26–73 19–74 15–77
128 (46.5) 134 (48.9) 134 (49.1)
147 (53.5) 140 (51.1) 139 (50.9)
47.8 (143.8) 332.9 (138.7) 347.9 (142.9)
128 (46.5) 126 (46.0) 128 (46.9)
47 (17.1) 40 (14.6) 41 (15.0)
100 (36.4) 108 (39.4) 104 (38.1)
3.21 (2.08) 3.46 (2.29) 3.33 (2.29)
0.09–10.65 0.08–13.73 0.23–10.88
3.04 (1.97) 3.29 (2.22) 3.17 (2.17)
0.05–10.31 0.08–13.73 0.21–10.88
3.31 (1.93) 3.51 (2.10) 3.43 (2.17)
0.37–10.31 0.28–13.73 0.23–10.88
larization; DA  disc areas; PRN  pro re nata; SD aselin
3
vascuatients in the 0.5 mg PRN group met criteria for retreatment at
t
[
t
g
t
w
w
a

t
C
a
e
1
P
3
m
r
e
o
(
r
(
s
F
t
O
l
i
Busbee et al  HARBOR Study 1-year Resultsany given monthly time point after month 2. The majority of these
patients (70% at each time point) met criteria on SD-OCT
examination alone (did not have a concomitant 5-letter BCVA
loss). A smaller percentage of patients (5.3%–13.8%) met retreat-
ment criteria based on BCVA loss of 5 letters alone at any given
monthly time point. This trend also was observed in the 2.0 mg
PRN group. At every time point with 1 exception, the percentage
of patients meeting retreatment criteria based on vision loss alone
was higher in the 2.0 mg group (11.0%–21.0%) compared with the
0.5 mg group.
Angiographic End Points. At 12 months, all 4 treatment
groups demonstrated a decrease from baseline in total area of CNV
and total area of CNV leakage. The change from baseline in total
area of CNV (DA) was a decrease of 2.14 (0.5 mg monthly), 1.74
(0.5 mg PRN), 2.42 (2.0 mg monthly), and 1.98 (2.0 mg PRN).
The change from baseline in total area of CNV leakage (DA) was
a decrease of 2.35 (0.5 mg monthly), 2.01 (0.5 mg PRN), 2.63 (2.0
mg monthly), and 2.22 (2.0 mg PRN).
Safety
Ocular Adverse Events. Ocular safety results are summarized in
Table 5. Serious ocular AEs in the study eye were rare across all
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0.5 mg PRN  
0.5 mg monthly  
2.0 mg monthly 
2.0 mg PRN  
Mean number of 
injections (SD)  
11.3 (1.8)
7.7 (2.7)
11.2 (2.1)
6.9 (2.4)
Mean ∆ in BCVA at
month 12 (Letters)
+10.1
+8.2
+9.2
+8.6
N
275
275
274
273
Figure 2. Mean change from baseline to month 12 in best-corrected visual
acuity (BCVA).* Vertical bars are1 standard error of the unadjusted mean.
The last-observation-carried-forward (LOCF) method was used to impute
missing data. *Mean number of injections was analyzed for patients who
received at least 1 ranibizumab injection in the study eye (n  274 treated
patients in 0.5 mg monthly group, n  275 treated patients in 0.5 mg pro re
nata (PRN) group, n 274 treated patients in the 2.0 mg monthly group, and
n 272 treated patients in the 2.0 mg PRN group). SD standard deviation.
Table 4. Key Visual Acu
0.
Mean change in BCVA from baseline, ETDRS letters (SD)
Proportion of patients gaining 15 letters from baseline, n (%)
Proportion of patients losing 15 letters from baseline, n (%)
Proportion of patients with Snellen 20/40, n (%)
Proportion of patients with Snellen 20/200, n (%)BCVA  best-corrected visual acuity; ETDRS  Early Treatment Diabetic Rereatment groups (endophthalmitis was reported by 2 patients
0.7%] in the 0.5 mg monthly group, and iridocyclitis and retinal
ear were reported by 1 patient [0.4%] each in the 2.0 mg monthly
roup). No new safety events were identified in any of the 4
reatment groups. There were no ocular SAEs of glaucoma. There
ere also no ocular SAEs of increased intraocular pressure (IOP),
hich was measured before injection, 30 (5) minutes after injection,
nd again at 60 (10) minutes post-injection if IOP was increased by
10 mmHg compared with the pre-injection measurement.
Ocular AEs (including those that were considered an SAE) in
he study eyes were balanced among all 4 treatment groups.
onjunctival hemorrhage was the most common ocular AE, with
n overall rate of 19% among the 4 treatment groups. Adverse
vents of increased IOP were reported in 4.0% (0.5 mg monthly),
.8% (0.5 mg PRN), 2.6% (2.0 mg monthly), and 2.2% (2.0 mg
RN) of patients. Post-dose IOP values of30 mmHg occurred in
.7%, 1.5%, 2.6%, and 1.9% of patients in the 0.5 mg monthly, 0.5
g PRN, 2.0 mg monthly, and 2.0 mg PRN treatment groups,
espectively. Other AEs of interest included glaucoma (0.4% in
ach treatment group) and iritis (0.6% overall). There was no trend
bserved for dose relationship (0.5 mg vs. 2.0 mg) or exposure
monthly vs. PRN) (Table 6, available at http://aaojournal.org).
Systemic Adverse Events. Systemic safety results are summa-
ized in Table 5, categorized by APTC ATE and AE of special interest
AESI) related to VEGF-A inhibition as defined in Genentech-
ponsored bevacizumab (Avastin) oncology trials and previously
nd Points at Month 12
Ranibizumab Treatment Groups
Monthly
275)
0.5 mg PRN
(n  275)
2.0 mg Monthly
(n  274)
2.0 mg PRN
(n  273)
13.3) 8.2 (13.3) 9.2 (14.6) 8.6 (13.8)
34.5) 83 (30.2) 99 (36.1) 90 (33.0)
97.8) 260 (94.5) 256 (93.4) 259 (94.9)
52.4) 127 (46.2) 137 (50.0) 119 (43.6)
7.3) 23 (8.4) 31 (11.3) 33 (12.1)
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igure 3. Mean change from baseline to month 12 in central foveal
hickness (CFT) by spectral-domain optical coherence tomography (SD-
CT). Vertical bars are 1 standard error of the unadjusted mean. The
ast-observation-carried-forward (LOCF) method was used to impute miss-
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Ophthalmology Volume 120, Number 5, May 2013described by Chen and Cleck.18 There was no obvious imbalance
across all 4 treatment groups in the rates of APTC ATEs and
AESIs.
The total rates of APTC-defined ATEs were low among the
treatment groups, ranging from 12 patients (4.4%) in the 0.5 mg
monthly group to 4 patients (1.5%) in the 0.5 mg PRN group, 6
patients (2.2%) in the 2.0 mg monthly group, and 8 patients (2.9%)
in the 2.0 mg PRN group. At year 1, 22 of the 1095 ranibizumab-
treated patients (2.0%) had died: 8 of 274 (2.9%) in the 0.5 mg
monthly group, 4 of 275 (1.5%) in the 0.5 mg PRN group, 5 of 274
(1.8%) in the 2.0 mg monthly group, and 5 of 272 (1.8%) in the 2.0
mg PRN group. The overall rates of nonfatal cerebrovascular
accidents were low (0.4%–0.7%) and similar among the 4 treat-
ment groups.
The overall rates of serious AESIs were similar among the 4
Table 5. A
0.5 mg M
(n 
Serious ocular AE in the study eye, n (%)
Any SAE* 3 (1
Reduced VA 0
Retinal hemorrhage 0
Endophthalmitis 2 (0
Corneal edema 0
Iridocyclitis 0
Macular degeneration 1 (0
Retinal artery occlusion 1 (0
Retinal tear 0
Retinal vein occlusion 1 (0
Vitreous floaters 0
APTC ATEs, n (%)
Total APTC events† 12 (4
Deaths, overall 8 (2
Vascular 6 (2
Unknown cause 1 (0
Nonfatal myocardial infarction 4 (1
Nonfatal CVA, overall 2 (0
Hemorrhagic CVA 1 (0
Ischemic CVA 1 (0
Serious AESI, n (%)
Any AESI‡ 16 (5
ATE 7 (2
Bleeding/hemorrhage (CNS) 2 (0
Bleeding/hemorrhage (non-CNS) 2 (0
Congestive heart failure 6 (2
Fistulae 0
Gastrointestinal perforation 0
Hypertension 0
Venous thrombotic events 1 (0
Wound healing complications 0
AE  adverse event; AESI  adverse event of special in
arterial thromboembolic event; CNS  central nervou
nata; SAE  serious adverse event; VA  visual acuit
AESI Classification: AEs related to VEGF-A inhibitio
bevacizumab (Avastin) oncology trials.
*Denotes total number of patients with 1 SAE. An A
prolonged hospitalization, resulted in persistent or signifi
by the investigating physician.
†Denotes total number of patients with 1 APTC ev
nonfatal myocardial infarctions, and nonfatal CVAs).
‡Denotes total number of patients with 1 serious AEtreatment groups, ranging from 4.7% to 5.8%. Rates of central w
1052ervous system–related bleeding events were similar among the 4
reatment groups: 2 patients (0.7%) in the 0.5 mg monthly group,
patients (0.7%) in the 0.5 mg PRN group, 1 patient (0.4%) in the
.0 mg monthly group, and 2 patients (0.7%) in the 2.0 mg PRN
roup. Serious AEs of hypertension also were uncommon, with 0
atients (0%) in the 0.5 mg monthly group, 1 patient (0.4%) in the
.5 mg PRN group, 1 patient (0.4%) in the 2.0 mg monthly group,
nd 2 patients (0.7%) in the 2.0 mg PRN group.
iscussion
he first objective of the HARBOR study was to assess the
fficacy of a higher ranibizumab dose in wet AMD, which
se Events
Ranibizumab Treatment Groups
ly 0.5 mg PRN
(n  275)
2.0 mg Monthly
(n  274)
2.0 mg PRN
(n  272)
3 (1.1) 6 (2.2) 1 (0.4)
2 (0.7) 3 (1.1) 0
1 (0.4) 1 (0.4) 1 (0.4)
0 0 0
1 (0.4) 0 0
0 1 (0.4) 0
0 0 0
0 0 0
0 1 (0.4) 0
0 0 0
0 1 (0.4) 0
4 (1.5) 6 (2.2) 8 (2.9)
4 (1.5) 5 (1.8) 5 (1.8)
3 (1.1) 2 (0.7) 1 (0.4)
0 0 1 (0.4)
0 2 (0.7) 4 (1.5)
1 (0.4) 2 (0.7) 2 (0.7)
0 0 0
1 (0.4) 2 (0.7) 2 (0.7)
13 (4.7) 16 (5.8) 13 (4.8)
5 (1.8) 6 (2.2) 7 (2.6)
2 (0.7) 1 (0.4) 2 (0.7)
2 (0.7) 4 (1.5) 4 (1.5)
2 (0.7) 2 (0.7) 2 (0.7)
1 (0.4) 1 (0.4) 0
0 1 (0.4) 0
1 (0.4) 1 (0.4) 2 (0.7)
1 (0.4) 2 (0.7) 0
1 (0.4) 0 0
; APTC  Antiplatelet Trialists’ Collaboration; ATE 
em; CVA  cerebrovascular accident; PRN  pro re
efined in Genentech Inc (South San Francisco, CA)
classified as an SAE if it cause or led to death, required
disability, or was considered a significant medical event
including vascular deaths, deaths of unknown cause,dver
onth
274)
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Busbee et al  HARBOR Study 1-year Resultsmg monthly and 0.5 mg monthly treatment groups. The
1-year results demonstrate that in patients with previously
untreated wet AMD, the ranibizumab 2.0 mg dose was not
superior to the 0.5 mg dose and did not offer any incremen-
tal improvement in efficacy outcomes. However, both doses
resulted in significant and clinically meaningful improve-
ments in mean BCVA. The increase in BCVA was 10.1
letters for the 0.5 mg monthly group and 9.2 letters for the
2.0 mg monthly group, with a model-adjusted mean differ-
ence of 1.1 letters (95.1% CI, 3.4 to 1.3; P  0.8145).
This result was unexpected, because several trials have
shown trends of a dose response with ranibizumab.6–8 Most
of the functional and anatomic outcomes favored the 0.5 mg
dose compared with the 0.3 mg dose of ranibizumab in the
pivotal phase III ANCHOR6,7 and MARINA8 studies.
Subsequent trials, such as the DoDo study and the SAVE10
trial, also showed trends in which higher ranibizumab doses
led to improved VA and anatomic outcomes. In the present
study, the robust results of the 0.5 mg monthly group
(among the highest gains seen in previous phase III studies)
and the lack of increased efficacy in the 2.0-mg group
suggest that the 0.5 mg monthly dose seems to be at the top
of the dose response for treatment-naïve patients with wet
AMD.
The second objective of HARBOR was to evaluate a
PRN dosing regimen with monthly evaluations. The 1-year
data resulted in a failure to meet NI (using a 4-letter margin)
for the 0.5 mg PRN and 2.0 mg PRN dose groups compared
with the 0.5 mg monthly dose group, with a model-adjusted
mean difference of2.0 letters (97.5% CI,4.5 to 0.6) and
1.6 letters (98.4% CI, 4.4 to 1.1), respectively. How-
ever, the VA outcomes for the PRN groups were clinically
meaningful, especially in the context of less-than-monthly
dosing. The 0.5 mg PRN group had an 8.2-letter gain that
was achieved using a mean of 7.7 injections over the 12
months, and the 2.0 mg PRN group had, on average, an
8.6-letter gain using a mean of 6.9 injections over the same
time period.
The HARBOR 1-year PRN data appear similar to the
ranibizumab PRN data published in year 1 of the CATT13
study. The CATT study was the first large, multicenter,
randomized, masked, NI trial designed to assess the relative
efficacy and safety of ranibizumab and bevacizumab and to
determine whether a PRN regimen would compromise long-
term VA outcomes compared with a monthly regimen. One
primary analysis in CATT was a comparison between
ranibizumab 0.5 mg monthly and ranibizumab 0.5 mg PRN.
In CATT, the PRN group was evaluated on a monthly basis
and retreated after the first loading dose when signs of
active neovascularization (defined as fluid on time-domain
OCT, new or persistent hemorrhage, decreased VA com-
pared with the preceding examination, dye leakage, or in-
creased lesion size on FA) were present.13 By using an NI
margin of 5 letters, the CATT investigators concluded that
ranibizumab 0.5 mg administered PRN with a monthly
evaluation had effects on vision at year 1 that were nonin-
ferior to those of ranibizumab administered monthly. The
CATT investigators reported gains of 8.5 letters (ranibi-
zumab 0.5 mg monthly) and 6.8 letters (ranibizumab 0.5 mg
PRN), with the mean difference of 1.7 letters (2-sided Vonferroni-adjusted 99.2% CI, 4.7 to 1.3). The CATT
anibizumab 0.5 mg PRN regimen achieved these gains
ith a mean of 6.9 injections over 1 year.
Although cross-trial comparisons have obvious limita-
ions, and data must be interpreted with caution, it is inter-
sting to note that CATT and HARBOR had different
onclusions on NI despite having similar study populations,
etreatment criteria, end points, and mean differences in
CVA at month 12 between the 0.5 mg monthly and 0.5 mg
RN groups. There were some differences between the
rials; for instance, CATT included patients with a Snellen
A between 20/25 and 20/320 (HARBOR inclusion was
nellen 20/40–20/320), featured a single loading dose
HARBOR had 3 loading doses), and used time-domain
CT (HARBOR used SD-OCT). However, a key difference
etween the 2 trials was the NI margin used in each study.
he HARBOR study was designed as an FDA registrational
rial, as well as to satisfy a post-marketing commitment, and
sed a 4-letter NI margin. In contrast, the CATT study was
esigned to compare the relative efficacy and safety of
anibizumab with bevacizumab, and used a 5-letter NI mar-
in, which was determined by the investigators to be the
aximum clinically acceptable true difference for new
reatments compared to active controls in the NI trials. This
-letter difference in the NI margins used in these 2 studies
ay have contributed to the different conclusions at year 1
egarding the NI of 0.5 mg PRN compared with 0.5 mg
onthly. However, regardless of which NI margin was
hosen, both of these studies showed that less-than-monthly
reatment regimens can decrease treatment burden and still
esult in clinically meaningful VA gains over 12 months.
Another recent set of studies evaluating ranibizumab
RN dosing were the VIEW 1/2 studies, which compared
flibercept (Eylea; Regeneron Pharmaceuticals Inc., Tarry-
own, NY) with ranibizumab in wet AMD for 2 years (Heier
S. 96-week results from the VIEW 1 and VIEW 2 studies:
ntravitreal aflibercept injection versus ranibizumab for neo-
ascular AMD shows sustained improvements in visual
cuity. Paper presented at: ARVO Annual Meeting, May 10,
012, Fort Lauderdale, FL). The VIEW 1/2 studies evalu-
ted different dosing regimens between the first and second
ears of the trials. During the first year of the trial, patients
ere treated with 3 different dosing regimens of aflibercept:
.5 mg every 4 weeks, 2.0 mg every 4 weeks, or 2.0 mg every
weeks (after 3 monthly loading doses) and were compared
ith patients treated with ranibizumab 0.5 mg every 4 weeks.
n the second year, all patients continued on their assigned
reatment drug and dose and were switched to a modified PRN
reatment regimen in which they were evaluated monthly with
mandatory retreatment at least every 12 weeks.
The 1-year results of the VIEW 1/2 studies found that
flibercept 2.0 mg dosed every 8 weeks after 3 initial
onthly loading doses was noninferior to ranibizumab 0.5
g dosed monthly. Patients receiving aflibercept 2.0 mg
osed every 8 weeks gained 8.4 letters from baseline at
eek 52 with an average of 7.5 injections,19 and finished the
tudy with an increase of 7.6 letters from baseline at week
6 with an average of 4.2 injections in the second year
modified PRN period) (Heier JS. 96-week results from the
IEW 1 and VIEW 2 studies: intravitreal aflibercept injec-
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Ophthalmology Volume 120, Number 5, May 2013tion versus ranibizumab for neovascular AMD shows sus-
tained improvements in visual acuity. Paper presented at:
ARVO Annual Meeting, May 10, 2012, Fort Lauderdale,
FL). In comparison, the ranibizumab 0.5 mg group (dosed
every 4 weeks) gained 8.7 letters from baseline at week 52
with an average of 12.3 injections,19 and ended the study
with a gain of 7.9 letters from baseline at week 96 with an
average of 4.7 injections in the second year (Heier JS.
96-week results from the VIEW 1 and VIEW 2 studies:
intravitreal aflibercept injection versus ranibizumab for neo-
vascular AMD shows sustained improvements in visual
acuity. Paper presented at: ARVO Annual Meeting, May 10,
2012, Fort Lauderdale, FL). Results from the second year of
the VIEW 1/2 studies suggest that ranibizumab and afliber-
cept are capable of producing similar visual outcomes using
a less-than-monthly treatment approach. Additional studies
would be warranted to definitely conclude the similarity
between these 2 anti-VEGF treatments.
In the context of historic, less-than-monthly dosing reg-
imens with ranibizumab, the HARBOR PRN groups re-
sulted in similar visual outcomes as those of the CATT
ranibizumab PRN group and better visual outcomes than the
quarterly dosing regimens of PIER11,12 and Safety Assess-
ment of Intravitreous Lucentis for AMD (SAILOR)20 (co-
hort 1). The HARBOR PRN groups also had similar results
to visual outcomes observed in the fixed monthly dose trials
in MARINA8 and ANCHOR.6,7 By looking at the evalua-
tion intervals of the 4 clinical trials with less-than-monthly
ranibizumab dosing groups (HARBOR, CATT, PIER and
SAILOR; Fig 4), it is evident that the durability of effect
with ranibizumab can be extended in many patients using
a closely monitored PRN regimen that incorporates
prompt recognition of recurrent OCT activity or decrease
in VA in contrast to loss of VA gains in a quarterly
fixed-dose regimen.
The HARBOR PRN data for both ranibizumab doses
suggest that prompt treatment of OCT fluid or visual decline
allows for sustained visual improvements over a 12-month
period. However, 2 points must be taken into account when
considering the PRN approach. First, the PRN groups did
not meet NI compared with the 0.5 mg monthly group in the
HARBOR trial. The results showed that treatment-naïve
patients with wet AMD treated monthly in the first year
gained, on average, approximately 2 letters more than pa-
tients treated PRN. In addition, patients in the 0.5 mg
monthly group also performed better on all secondary and
exploratory VA end points relative to the PRN groups
(Table 4). Physicians and patients will need to take into
consideration this benefit/risk in the context of decreased
injection frequency when deciding to treat with ranibizumab
0.5 mg monthly versus PRN. Second, the durability of the
VA gains achieved with PRN dosing beyond 12 months in
HARBOR is unknown, but this will be answered at the
completion of the HARBOR trial.
The third objective of the HARBOR trial was to evaluate
the safety of the 0.5 mg and 2.0 mg doses administered on
a monthly and PRN schedule. Overall, the incidence of
ocular AEs observed in HARBOR was consistent with
previous ranibizumab trials in wet AMD and was compa-
rable among groups. There were no apparent dose-related S
1054rends between the 0.5 mg and 2.0 mg groups. Moreover,
here were no apparent dose-exposure–related trends be-
ween the monthly and the PRN groups. Serious ocular AEs
n the study eye were rare for both the 0.5 mg and 2.0 mg
reatment groups, with endophthalmitis reported in 2 pa-
ients (0.5 mg monthly group), retinal hemorrhage reported
n 3 patients (1 patient each in the 0.5 mg PRN, 2.0 mg
onthly, and 2.0 mg PRN groups), and iridocyclitis and
etinal tear reported in 1 patient each in the 2.0 mg monthly
roup. Other serious ocular AEs reported in the study eye
re shown in Table 5.
The IOP events in HARBOR are of particular interest
ecause there have been recent reports of increased pre-dose
OP in a subset of wet AMD patients treated with ranibi-
umab21 (Bakri S, Moshfeghi DM, Francom S, et al. Intra-
cular pressure (IOP) in eyes receiving monthly intravitreal
anibizumab in the MARINA and ANCHOR trials. Paper
resented at: AAO Annual Meeting, October 24, 2011,
rlando, FL; Bakri S, Moshfeghi DM, Francom S, et al.
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igure 4. Mean change in best-corrected visual acuity (BCVA) from
aseline at month 12 across select wet age-related macular degeneration
AMD) trials evaluating less-than-monthly ranibizumab dosing regimens.
Ranibizumab 0.5 mg administered as 3 monthly loading doses followed by
ro re nata (PRN) dosing. Vertical bars are 1 standard error of the
nadjusted mean. The last-observation-carried-forward (LOCF) method
as used to impute missing data. †Ranibizumab 0.5 mg administered as 1
oading dose, followed by PRN dosing. Vertical bars are 1 standard error
f the mean. ‡Treatment-naïve patients in cohort 1 received 3 monthly
oading doses of ranibizumab 0.5 mg followed by protocol-defined retreat-
ent. Vertical bars are 1 standard error of the unadjusted mean. The
OCF method was used to impute missing data. #Ranibizumab 0.5 mg
dministered at day 0 and months 1, 2, 5, 8, and 11. Vertical bars are 1
tandard error of the unadjusted mean. The LOCF method was used to
mpute missing data. CATT  comparison of age-related macular degen-
ration treatments trials; HARBOR  phase III, double-masked, multi-
enter, randomized, active treatment-controlled study of the efficacy and
afety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an
s-needed basis (PRN) in patients with subfoveal neovascular age-related
acular degeneration; PIER  phase IIIb, multicenter, randomized, dou-
le-masked, sham injection-controlled study of the efficacy and safety of
anibizumab in subjects with subfoveal choroidal neovascularization with
r without classic choroidal neovascularization (CNV) secondary to age-
elated macular degeneration study; SAILOR  safety assessment of
ntravitreous lucentis for AMD. , HARBOR*; , CATT†; Œ,
AILOR‡; and , PIER#.
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Busbee et al  HARBOR Study 1-year ResultsAnalysis of intraocular pressure in eyes receiving monthly
intravitreal ranibizumab in the MARINA and ANCHOR
Trials. Paper presented at: ASRS Annual Meeting, August
22, 2011, Boston, MA). No serious ocular AEs of increased
IOP were reported in HARBOR. The percentage of patients
with nonserious ocular AEs of increased IOP ranged from
1.8% to 4.0% and was highest in the 0.5 mg monthly group,
demonstrating that there was no increase of IOP-related
AEs at higher ranibizumab doses. Furthermore, none of the
4 treatment groups showed an increase in mean pre-dose
IOP from baseline to month 12 (Fig 5). In terms of glau-
coma, no serious ocular AEs of glaucoma were reported and
the incidence of reported ocular AEs of glaucoma was low,
with 0.4% in each of the 4 treatment groups. From these
data, it seems that during the first year of HARBOR, IOP
and glaucoma events were not of obvious concern for the
standard or the higher dose of ranibizumab.
Systemic AEs also were consistent with previous ranibi-
zumab trials in wet AMD. Similar to the ocular AEs, the
rates of systemic AEs were comparable between groups,
with no apparent dose-related or dose-exposure trends ob-
served even with a 4-fold higher dose. Ranibizumab ap-
peared safe when used at the standard or the higher dose, as
well as when administered monthly or PRN during the
HARBOR trial.
There are several limitations of the HARBOR study. One
limitation is a fairly homogenous US study population. A
second limitation is that the 1-year data from HARBOR
cannot predict visual outcomes in future years. However,
HARBOR is an ongoing, 2-year study and will provide data
on the long-term durability of ranibizumab with a PRN
regimen. Third, although no new safety events were detected,
the HARBOR study was not powered to detect statistical
differences between treatment groups. Finally, although the
PRN dosing regimen decreased treatment burden and pro-
duced clinically relevant visual gains, monthly monitoring was
required to achieve these gains. Investigations around treat-
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Figure 5. Mean pre-dose intraocular pressure (IOP) in the study eye
during the first 12-month treatment period. The mean pre-dose IOP in the
study eye over the first 12 months was in the range of 14.3 to 15.3 mmHg,
and the standard error was 0.2 at each visit. PRN  pro re nata.ment approaches that decrease both injection and visit fre-uency (e.g., treat and extend or sustained delivery) are of
ontinued interest in the treatment of wet AMD.
In conclusion, the HARBOR study adds to the growing
ody of clinical trial data that are available for ranibizumab
n wet AMD. Although the PRN cohorts did not meet the
respecified NI comparison and the 2.0 mg monthly group
id not meet the prespecified superiority comparison, the
ARBOR Study 1-year results demonstrate clinically
eaningful improvements in VA and anatomic outcomes
cross all 4 treatment groups. The HARBOR study demon-
trated that the 2.0 mg dose of intravitreal ranibizumab has
n acceptable safety profile comparable to that of the stan-
ard dose. Although less effective than monthly dosing,
RN dosing using SD-OCT–guided retreatment criteria de-
reased treatment burden and produced clinically meaning-
ul VA gains in patients with wet AMD. The HARBOR
esults ultimately confirmed that the current, commercially
vailable preparation of ranibizumab (0.5 mg), when dosed
onthly, provides optimum results.
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